Background: A revision of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification for lupus nephritis has been published in 2018. The current study aimed to verify the utility of this system. Materials and Methods: A total of 101 lupus nephritis patients from a large Chinese cohort who underwent renal biopsy in Peking University First Hospital were reevaluated by 2 renal pathologists, who had no knowledge of the clinical findings. The association between clinical data at the time of initial renal biopsy and follow-up and pathological features were further analyzed on all patients selected. Results: The mean age of the cohort was 33 years with a male/female ratio of 1:9, and a median follow-up period of 128 months. The presence and extent of mesangial hypercellularity, endocapillary hypercellularity, global and segmental glomerulosclerosis, neutrophil exudation/karyorrhexis, glomerular hyaline deposits, extracapillary proliferation (crescents), tubular atrophy/interstitial fibrosis, and interstitial inflammation were significantly correlated with several clinical renal injury indices (systemic lupus erythematosus disease activity index, serum creatinine value, proteinuria, and C3 level) at the time of biopsy. By multivariable Cox hazard analysis, fibrous crescents, tubular atrophy/interstitial fibrosis, and the modified National Institutes of Health chronicity index were independent risk factors for patients’ composite renal outcomes (hazard ratio [HR] 4.100 [95% CI 1.544–10.890], p = 0.005; HR 8.584 [95% CI 2.509–29.367], p = 0.001; and HR 3.218 [95% CI 1.138–9.099], p = 0.028; respectively). Conclusions: The 2018 revision of the ISN/RPS classification for lupus nephritis has utility for prediction of clinical renal outcomes.

Keywords:
Lupus nephritis, Classification, Pathologic lesions, Prognosis
1.
Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.
Kidney Int
. 2010 May;77(9):820–9.
2.
Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions.
Kidney Int
. 2013 Apr;83(4):715–23.
3.
Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis.
Kidney Int
. 2009 Aug;76(3):307–17.
4.
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited.
Kidney Int
. 2004 Feb;65(2):521–30.
5.
Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.
Nat Rev Nephrol
. 2017 Aug;13(8):483–95.
6.
Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
Kidney Int
. 2018 Apr;93(4):789–96.
7.
Wilhelmus S, Alpers CE, Cook HT, Ferrario F, Fogo AB, Haas M, et al. The revisited classification of GN in SLE at 10 years: time to re-evaluate histopathologic lesions.
J Am Soc Nephrol
. 2015 Dec;26(12):2938–46.
8.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
Arthritis Rheum
. 1997 Sep;40(9):1725.
9.
Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.
Arthritis Rheum
. 1989 Sep;32(9):1107–18.
10.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al.; The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients.
Arthritis Rheum
. 1992 Jun;35(6):630–40.
11.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
Kidney Int
. 2007 Aug;72(3):247–59.
12.
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis—a new look at an old entity.
N Engl J Med
. 2012 Mar;366(12):1119–31.
13.
Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies.
Nat Rev Nephrol
. 2015 Jan;11(1):14–22.
14.
Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.
J Immunol
. 2011 Feb;186(3):1849–60.
15.
Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al.; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.
Kidney Int
. 2009 Sep;76(5):546–56.
16.
Holm S. A simple sequentially rejective multiple test procedure.
Scand J Stat
. 1979;6:65–70.
17.
Norman G, Streiner D. Biostatistics, The Bare Essentials. Hamilton, Ontario: BC Decker Inc; 2000.
18.
Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome.
Kidney Int
. 1984 Apr;25(4):689–95.
19.
Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Disease. 2nd ed. New York: Igaky-Shoin; 1995.
20.
Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, et al.; Kanazawa Study Group for Renal Diseases and Hypertension. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese.
Kidney Int
. 2004 Dec;66(6):2382–8.
21.
Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?
Am J Kidney Dis
. 2004 Dec;44(6):1050–9.
22.
Hill GS, Delahousse M, Nochy D, Bariéty J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis.
Kidney Int
. 2005 Nov;68(5):2288–97.
23.
Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years.
Kidney Int
. 2007 Mar;71(6):491–5.
24.
Hiramatsu N, Kuroiwa T, Ikeuchi H, Maeshima A, Kaneko Y, Hiromura K, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.
Rheumatology (Oxford)
. 2008 May;47(5):702–7.
25.
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al.; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.
Kidney Int
. 2009 Sep;76(5):534–45.
26.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al.; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group.
Kidney Int
. 2017 May;91(5):1014–21.
27.
Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data.
Am J Med
. 1983 Sep;75(3):382–91.
28.
Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.
Arthritis Care Res (Hoboken)
. 2011 Jun;63(6):865–74.
29.
Alsuwaida AO. Interstitial inflammation and long-term renal outcomes in lupus nephritis.
Lupus
. 2013 Dec;22(14):1446–54.
30.
Hill GS, Delahousse M, Nochy D, Mandet C, Bariéty J. Proteinuria and tubulointerstitial lesions in lupus nephritis.
Kidney Int
. 2001 Nov;60(5):1893–903.
31.
Hill GS, Delahousse M, Nochy D, Rémy P, Mignon F, Méry JP, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages.
Kidney Int
. 2001 Jan;59(1):304–16.
32.
Zappitelli M, Duffy CM, Bernard C, Gupta IR. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis.
Pediatr Nephrol
. 2008 Jan;23(1):83–91.
33.
Zhang X, Nagaraja HN, Nadasdy T, Song H, McKinley A, Prosek J, et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies.
Kidney Int
. 2012 Feb;81(4):401–6.
34.
Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in Systemic Lupus Erythematosus.
Curr Opin Immunol
. 2016 Dec;43:32–8.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.